20 September 2023
20 September 2023
European Commission has approved the oral combination drug for treating newly diagnosed acute myeloid leukaemia.
UK public sector doctor's pay is below that in Germany or the US, and ongoing strike action may lead to more emigration.
The company will suspend the development of three assets, considering strategic alternatives for two clinical programmes.
The approval was based on data from the ALLEGRO clinical trial programme, which included the ALLEGRO Phase IIb/III study.
The regulator is due to provide a decision on the approval of the treatment by 17 January 2024.
BeiGene has regained complete global rights to TEVIMBRA, without owing royalties to Novartis.
PeptiDream will oversee the initial preclinical activities linked to the development of peptide-RI drug conjugate products.
The company plans to refile the IND after assessing the feasibility of US FDA-suggested trial modifications.
Offering the perfect platform for professionals from across a range of clinical trial functions to meet, network, and hear about latest developments.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.
Give your business an edge with our leading industry insights.
